Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size no exceeding 50 ?m; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 ?m, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The invention concerns a floating pharmaceutical composition consisting of at least a first phase comprising at least a high dose active principle combined with one or several carriers and at least a second phase comprising at least a gas-generating system. The invention also concerns tablets comprising such a pharmaceutical composition and a method for preparing such tablets.

Abstract: This invention relates to an impregnated powder for increasing the bioavailabilty and/or the solubility of at least one active principle comprising a solid, inert support in a particle form impregnated by a liquid medium comprising a hydrophobic phase and optionally a hydrophilic phase, at least one surfactant and at least one active principle dissolved in at least one of said phases, wherein said active principle(s) is(are) also present in at least one of said phases in the form of a suspension. Such an impregnated powder is used as a base for various preparations in the pharmaceutical, parapharmaceutical and cosmetic field, in the food complement field and in the food processing industry.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 ?m; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 ?m, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The invention relates to an immediate release dispersible and orodispersible solid pharmaceutical composition having the form of particles with a size lower than 710 ?m, containing the metformin active ingredient, characterized in that it comprises: a) from 65% to 90% in weight of the metformin active ingredient, optionally under the form of a salt, or a combination of the metformin active ingredient with a hypoglycemic active ingredient; b) from 0.5 to 4% in weight of a binding agent or a combination of binding agents; c) from 1% to 12% in weight of a disintegrating agent or a combination of disintegrating agents; d) from 0% to 10% in weight of a diluting agent or a combination of diluting agents; e) from 0.05% to 3% in weight of a sweetening agent or a combination of sweetening agents; and f) one or more additional excipients, the weight percentages being expressed based on the total weight of said composition.

Abstract: The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same.

Abstract: The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same.

Abstract: This invention relates to an impregnated powder for increasing the bioavailabilty and/or the solubility of at least one active principle comprising a solid, inert support in a particle form impregnated by a liquid medium comprising a hydrophobic phase and optionally a hydrophilic phase, at least one surfactant and at least one active principle dissolved in at least one of said phases, wherein said active principle(s) is(are) also present in at least one of said phases in the form of a suspension. Such an impregnated powder is used as a base for various preparations in the pharmaceutical, parapharmaceutical and cosmetic field, in the food complement field and in the food processing industry.

Abstract: A method for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, optionally in combination with a second active ingredient, in the form of tablets, characterized in that it comprises a compression step of the active ingredient and excipients by means of a dry method of granulation

Abstract: The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane for preventing or treating radiotherapy-related and chemotherapy-related mucositis, induced by radiotherapy or combined radiochemotherapy, comprising an effective amount of an antiradical compound mixed with a vehicle, which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled status.

Abstract: The invention concerns a micronized pharmaceutical or nutraceutical powder with immediate release having a grain size distribution of not more than 100 ?m, and comprising the combination of at least an active substance, at least a wetting agent and at least a diluent.

Abstract: The present invention relates to a micronized film-forming powder having a particle size of at most 100 ?m and comprising a combination of at least one active substance, at least one bioadhesive agent, and at least a plasticizer.

Abstract: The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Abstract: The invention concerns a progestin co-micronized with a surfactant and a pharmaccutical composition comprising said gestagenic. The invention also concerns methods for preparing same.